IDEXX stock price target raised to $530 at BTIG
BTIG analyst Mark Massaro announced an increased price target for IDEXX Laboratories (NASDAQ:IDXX), raising it from $500 to $530, while maintaining a Buy rating on the stock. The revision follows ...
Le Lézard15h
HOPE Therapeuticstm, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Engage BTIG as Financial Advisor
HOPE has announced plans to assemble a best-in-class global network of interventional psychiatry clinics combining ketamine treatment with transcranial magnetic stimulation, and digital therapeutics ...
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Engage BTIG as Financial Advisor
HOPE Therapeutics™, Inc. ("HOPE"), a medical and technology driven company, and a wholly-owned subsidiary of NRx ...
InMode to Participate in the BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference
InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer will host investor meetings at the BTIG MedTech, ...
DraftKings price target raised to $59 from $55 at BTIG
BTIG analyst Clark Lampen raised the firm’s price target on DraftKings (DKNG) to $59 from $55 and keeps a Buy rating on the shares as part of a ...
BTIG Keeps Their Buy Rating on DraftKings (DKNG)
In a report released today, Clark Lampen from BTIG maintained a Buy rating on DraftKings (DKNG – Research Report), with a price target of ...
BTIG cuts IQVIA stock rating to neutral amid sector headwinds
BTIG analyst David Larsen adjusted the firm's stance on IQVIA Holdings (NYSE:IQV), moving from a Buy rating to Neutral. The $36.5 billion market cap company, currently trading near its 52-week low at ...